8-K: Charles River Laboratories Reports Mixed Q4 and Full-Year 2023 Results, Provides 2024 Guidance

Charles River Laboratories announced a decrease in fourth-quarter revenue and provided 2024 guidance, reflecting a cautious biopharmaceutical demand environment.

Summary

• Charles River Laboratories reported a fourth-quarter revenue of $1.01 billion, a 7.9% decrease compared to the same period in 2022.
• Full-year 2023 revenue reached $4.13 billion, a 3.9% increase from 2022, with organic revenue growth of 6.5%.
• Fourth-quarter GAAP earnings per share were $3.62, a slight decrease from $3.65 in 2022, while non-GAAP earnings per share were $2.46, down from $2.98.
• Full-year GAAP earnings per share were $9.22, down from $9.48 in 2022, and non-GAAP earnings per share were $10.67, down from $11.12.
• The company's 2024 guidance projects revenue growth between 1.0% and 4.0%, with organic revenue growth between 0.0% and 3.0%.
• Non-GAAP earnings per share for 2024 are estimated to be between $10.90 and $11.40, benefiting from the Noveprim acquisition.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the mixed results, with revenue declines in Q4 and reduced earnings, but with positive future guidance and strategic acquisitions.

Positives

• Full-year revenue increased by 3.9% to $4.13 billion, with organic revenue growth of 6.5%.
• The Manufacturing segment saw organic revenue growth of 2.3% in the fourth quarter.
• The Noveprim acquisition is expected to positively impact 2024 non-GAAP earnings per share by at least $0.30.
• The company is focused on innovation and enhancing its portfolio to support clients from target discovery to non-clinical development.
• Charles River believes the current market environment is transitory and expects demand to stabilize in 2024.

Negatives

• Fourth-quarter revenue decreased by 7.9% year-over-year.
• Organic revenue decreased by 3.5% in the fourth quarter.
• GAAP and non-GAAP operating margins decreased in the fourth quarter, primarily due to higher unallocated corporate costs.
• Non-GAAP net income and earnings per share decreased in the fourth quarter and full year, driven by lower revenue and operating income.
• The Discovery and Safety Assessment (DSA) segment experienced a significant revenue decline in the Discovery Services business.
• The Manufacturing segment's revenue decreased by 9.5% in the fourth quarter, impacted by the Avian Vaccine divestiture.

Risks

• The company faces potential risks related to non-human primate (NHP) supply constraints and investigations by the U.S. government into the NHP supply chain.
• There are uncertainties in the global economy and financial markets that could impact the company's performance.
• The company's ability to successfully integrate acquired businesses, including Noveprim, is a risk.
• Negative trends in research and development spending or cost reduction actions by clients could affect revenue.
• The company is exposed to risks related to interest rate and foreign currency exchange rate fluctuations.
• Changes in tax regulations and laws could impact the company's financial results.

Future Outlook

The company anticipates a continuation of cautious biopharmaceutical demand in 2024, but expects demand to stabilize over the year. They project revenue growth between 1.0% and 4.0% and non-GAAP EPS between $10.90 and $11.40 for 2024.

Management Comments

• Our 2023 performance demonstrated the resilience and stability of our strategy and business model.
• Despite moderating demand trends in the broader life sciences sector, we were able to deliver solid revenue growth and non-GAAP earning per share that were in the upper half of our original guidance ranges.
• We are focused on innovation, enhancing our portfolio to support clients from target discovery to non-clinical development, and delivering flexible solutions to respond to a changing industry and client requirements.
• We believe the current market environment is transitory.
• We are anticipating that some level of constrained client spending will persist in 2024, but that demand will stabilize over the course of the year.
• The long-term industry fundamentals for drug development remain firmly intact, which supports our goals to deliver sustained revenue growth and solid operating margin improvement in 2024 and in the future.

Industry Context

The announcement reflects the broader trend of moderating demand in the life sciences sector, impacting companies involved in drug discovery and development. Charles River's focus on innovation and portfolio enhancement aligns with the industry's need for flexible solutions and comprehensive services.

Comparison to Industry Standards

• Charles River's revenue growth of 3.9% for the full year is below the high single-digit growth seen by some CROs (Contract Research Organizations) like ICON plc and IQVIA in recent years, but is in line with the more moderate growth seen by the sector as a whole.
• The company's non-GAAP operating margin of 20.3% for the full year is comparable to other large CROs, but is lower than the margins of some specialized service providers.
• The decrease in organic revenue in the fourth quarter is a concern, as many CROs have been reporting strong organic growth, suggesting that Charles River may be facing specific challenges in certain segments.
• The acquisition of Noveprim is a strategic move to secure the supply of non-human primates, which is a critical resource for drug development, and is similar to moves made by other companies to secure their supply chains.

Legal Proceedings

• The company is facing investigations by the U.S. government into the NHP supply chain related to their Safety Assessment business.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and earnings, but may be encouraged by the 2024 guidance and strategic acquisitions.
• Employees may be affected by restructuring actions and site consolidations.
• Customers may experience changes in service offerings due to the company's focus on innovation and portfolio enhancement.
• Suppliers may be impacted by the company's efforts to secure its supply chain, particularly for NHPs.

Next Steps

• The company will continue to focus on opportunities to win additional market share.
• They will focus on driving efficiencies to be a more compelling partner for clients.
• Charles River will continue to assess the potential value of reporting non-GAAP results.
• The company will host a live webcast on February 14th to discuss the results.

Key Dates

Keywords

pharmaceutical, biotechnology, drug development, research models, safety assessment, manufacturing solutions, non-human primates, revenue, earnings per share, organic growth, Noveprim, acquisition, financial results, guidance